Disease and treatment burden of patients with haemophilia entering the explorer6 non-interventional study
- PMID: 39030946
- DOI: 10.1111/ejh.14277
Disease and treatment burden of patients with haemophilia entering the explorer6 non-interventional study
Abstract
Objectives: We aimed to characterise baseline disease and treatment burden in a large population with haemophilia A/B, both with (HAwI/HBwI) and without (HA/HB) inhibitors.
Methods: The prospective, non-interventional explorer6 study included patients ≥12 years old with severe HA, severe/moderate HB or HAwI/HBwI of any severity, treated according to local standard of care (excluding previous/current exposure to concizumab or emicizumab). Baseline characteristics and historical clinical data were collected and patient-reported outcomes, including treatment burden, were assessed.
Results: The explorer6 study enrolled 231 patients with haemophilia (84 HAwI/HBwI) from 33 countries. At baseline, patients with HA/HB treated with prophylaxis had the lowest median annualised bleeding rates (ABRs; 2.0), irrespective of haemophilia type; of these patients, 27.5% (HA) and 31.4% (HB) had target joints. Patients with HAwI/HBwI treated episodically reported the highest treatment burden. Of these patients, 28.5% (HAwI) and 25.1% (HBwI) performed sports activities in the month before screening.
Conclusion: Despite receiving routine clinical care, historical and baseline information from patients enrolled in explorer6 showed that patients with HA/HB treated episodically and patients with HAwI/HBwI had higher ABRs, higher treatment burden and participated in sports less than those with HA/HB treated with prophylaxis. Emerging treatments could be beneficial in addressing these unmet medical needs.
Keywords: haemophilia A; haemophilia B; health‐related quality of life; physical activity; symptom burden.
© 2024 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: current knowledge and future perspectives. J Thromb Haemost. 2021;19(9):2112‐2121.
-
- Kloosterman F, Zwagemaker AF, Abdi A, Gouw S, Castaman G, Fijnvandraat K. Hemophilia management: huge impact of a tiny difference. Res Pract Thromb Haemost. 2020;4(3):377‐385.
-
- Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1‐158.
-
- Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adherence. 2017;11:1677‐1686.
-
- Putz P, Klinger M, Male C, Pabinger I. Lower physical activity and altered body composition in patients with haemophilia compared with healthy controls. Haemophilia. 2021;27(2):e260‐e266.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical